The newly approved RSV vaccine could be rolled out by fall 2023, in time for the typical winter surge in RSV infections.

The new bivalent boosters against COVID-19 have failed to halt omicron infections. However, new technologies are being developed that pave a way forward.

The FDA’s authorization of the reformulated COVID-19 booster shots represents a major step in the effort to get more Americans boosted.

The FDA’s authorization of the reformulated COVID-19 booster shots represents a major step in the effort to get more Americans boosted.

Early on, public health messaging focused on the need for vaccines to combat COVID-19. But far less attention has been given to the role of boosters in preventing deaths and reducing inequities.

On the horizon: A new omicron-focused version of the Moderna vaccine that may offer longer protection and a stronger immune response.

The FDA’s authorization of COVID-19 shots for children ages 6 months to 4 years will bring relief for millions of parents. Pending CDC endorsement, shots for this group will be available within days.

The COVID-19 vaccines continue to be effective against severe illness leading to hospitalization and death in all age groups, including children ages 5 to 11.

Moderna will ask the FDA to allow emergency use for its vaccine in children as young as 6 months, a step many parents have been anticipating.

The COVID-19 pandemic has brought immunology terms that are typically relegated to textbooks into our everyday vernacular. These stories helped us make sense of the ever-evolving science.